Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Congressman Eric Swalwell Awards Cerebrotech Medical Systems Special Congressional Recognition for Innovation and Economic Growth

Cerebrotech Medical Systems,Inc.
Posted on: 07 Dec 17

Cerebrotech Medical Systems, an innovative medical device company focused on the development of a portable brain bioimpedance monitor, has received a Special Congressional Recognition by U.S. Congressman Eric Swalwell for achieving the 2017 “Economic Driver” award from the Chamber of Commerce of Pleasanton, CA, where the neurotechnology solution company is located.

“Congratulations to Cerebrotech for achieving this award. I am very proud of the great innovation taking place here in Pleasanton at groundbreaking startup medical device companies like Cerebrotech,” said Pleasanton Mayor Jerry Thorne. “These companies are developing revolutionary technologies that will make important advances for the future of medical care.”

“Cerebrotech’s innovative technology has the ability to drastically change the paradigm of care for patients at high risk of stroke and brain damage, and we are honored to be recognized for the company’s potential impact in our hometown,” remarked Cerebrotech’s Medical System’s Chief Executive Officer, Mitch Levinson. “Cerebrotech is the third medical device company I have been fortunate enough to help start right here in Pleasanton. These companies have been able to take advantage of the innovative infrastructure of the Bay Area, and tap into the pool of technical employees who enjoy the more balanced lifestyle of the Tri-Valley cities like Pleasanton.”

Cerebrotech’s technological innovation is focused on creating and commercializing a portable brain bioimpedance monitor. This monitor is being designed to improve outcomes for stroke patients by providing real-time assessments critical to assessment and recovery. Implementation of its core technology, Volumetric Integral Phase-shift Spectroscopy (VIPS™), will allow for earlier intervention, and reduce recovery time and hospital costs. Using Cerebrotech’s proprietary machine learning technology, the company plans to train its wireless, portable Intracranial Fluids Monitor™ to detect a variety of neurological conditions, including stroke, cerebral edema, traumatic brain injury, hydrocephalus, concussion and brain tumors non-invasively. The device holds a CE Mark, and is not yet cleared for sale in the United States.

About Cerebrotech Medical Systems

Cerebrotech Medical Systems, Inc., is a venture capital-backed company dedicated to designing neurotechnology solutions to improve the care of brain-injured patients worldwide. The company is developing a portable, noninvasive neuro-monitoring device that allows for earlier detection of potentially life-threatening conditions such as large vessel occlusion stroke, cerebral edema, traumatic brain injury, and others. Founded in 2010 and based in Pleasanton, CA, Cerebrotech’s core intellectual property is licensed exclusively from the University of California at Berkeley. Cerebrotech is backed by Tri-Star Health Partners, a healthcare focused venture capital firm, Mountain Group Partners, a life sciences and technology focused venture capital firm, Neuro Technology Investors, a group of physician investors in the neuro space. For more information, visit

View source version on

Business Wire

Last updated on: 07/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.